Nuvalent, Inc. · 14 hours ago
Director, Field Health Economics & Outcomes Research (HEOR)
United States
Full-time
Remote
Director/Executive
$220K/yr - $250K/yr
7+ years expNuvalent, Inc. is an exciting early-stage company focused on creating selective medicines for cancer patients. The Director of Health Economics & Outcomes Research will lead U.S. and Global HEOR strategy, shaping value evidence for optimal patient access and informing coverage and reimbursement decisions.
BiotechnologyLife ScienceTherapeutics
Responsibilities
Lead the U.S. & Global HEOR strategy and integrated evidence planning for Nuvalent assets, aligned with Medical Affairs, Market Access, Regulatory, and Commercial priorities
Standardize and optimize data generation policies, processes, and SOPs to ensure quality, compliance, and scalability
Develop the annual HEOR tactical plan and budget; manage timelines, vendors, and scope to achieve defined objectives
Serve as the internal HEOR point of contact for evidence generation needs, services, and technologies; proactively represent payer/IDN evidence needs in cross-functional planning
Educate and upskill teams on HEOR, evidence-based medicine, U.S. reimbursement trends, and Global HTA dynamics
Design, lead, and complete HEOR/RWE studies (e.g., observational studies, claims/EMR/registry analyses, PRO development/validation, burden of illness, unmet need)
Own research plans, protocols, budgets, and timelines; oversee analyses and author abstracts, posters, manuscripts, and internal reports
Partner with Clinical Development and Biostatistics/Evidence Generation to optimize study design, endpoints, data sources, and analyses
Collaborate with Medical Information/Scientific Communications to inform U.S./Global publication plans and ensure consistent, compliant value messaging
Lead development of AMCP/Global dossiers, Budget Impact Models (BIMs), Cost-Effectiveness Analyses (CEA), ITCs/NMAs, Systematic Literature Reviews (SLRs), and payer pull-through materials
Support ICER assessments and responses (as applicable) and monitor HTA implications (e.g., NICE, CADTH, etc.) for brand strategy
Identify and collaborate with KOLs/COEs on study design, authorship, and advisory boards; conduct payer advisory boards to track evolving evidence requirements
Engage payers, IDNs, PBMs, specialty pharmacies, and other decision makers via compliant scientific exchange to inform evidence needs and communicate value
Provide field-based scientific/HEOR support and tools to Market Access and medical field teams
Partner with Brand/Commercial and Market Access to shape value narratives and pull-through while maintaining scientific integrity and compliance
Contribute to or lead high-priority medical initiatives, integrated evidence planning workshops, advisory boards, and cross-functional launch planning across U.S. and Global teams
Maintain in-depth knowledge of the evolving healthcare environment and HTA to anticipate evidence needs and inform strategy
Qualification
Required
Doctoral degree (PhD, PharmD, MD/DO)
7–10+ years of relevant pharma/biotech HEOR/RWE experience
Oncology experience (3+ years), preferably NSCLC; U.S. and Global launch experience
Demonstrated expertise with U.S. and Global RWD (claims, EMR, registries) and payer landscapes
Hands-on experience with HEOR modeling (BIM/CEA), observational methods, and PROs; familiarity with statistics
Proven ability to work independently and collaboratively in fast-paced, cross-functional environments and manage multiple complex projects
Outstanding communication and presentation skills, including executive-level briefings and external thought leader engagement
U.S.-based remote role with periodic travel for internal meetings, congresses, advisory boards, and select payer/KOL engagements (~10–20% domestic; occasional international as needed)
Preferred
Experience supporting ICER and engaging with Global HTA bodies (e.g., NICE, CADTH)
Track record building departmental capabilities, SOPs, and scalable vendor/operational frameworks
Established relationships across payers/IDNs/PBMs and oncology KOLs/COEs
Knowledge of medical communications trends and best practices
Benefits
Medical, dental, and vision insurance
401(k) retirement savings plan
Generous paid time off (including a summer and winter company shutdown)
Company
Nuvalent, Inc.
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets.
51-200 employees
Funding
Current Stage
Public CompanyTotal Funding
$1.82BKey Investors
Bain Capital Life SciencesDeerfield
2025-11-18Post Ipo Secondary· $500M
2024-09-16Post Ipo Equity· $575M
2023-10-16Post Ipo Equity· $300M
Leadership Team
James Porter
CEO
Alexandra Balcom
Chief Financial Officer
Recent News
MarketScreener
2025-12-16
Company data provided by crunchbase